Home pageALNOV • EPA
Novacyt
0,73 €
30 set, 13:19:11 GMT+2 · EUR · EPA · Disclaimer
Titolo azionarioTitolo quotato in FR
Chiusura precedente
0,75 €
Intervallo giornaliero
0,72 € - 0,76 €
Intervallo annuale
0,45 € - 1,59 €
Cap di mercato
52,40 Mln EUR
Volume medio
2,09 Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
EPA
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(GBP)dic 2023Variazione Y/Y
Entrate
4,12 Mln81,82%
Spese di gestione
12,52 Mln48,31%
Utile netto
-9,97 Mln-17,10%
Margine di profitto netto
-242,0435,59%
Utili per azione
EBITDA
-7,10 Mln-41,10%
Aliquota fiscale effettiva
2,93%
Totale attivo
Totale passivo
(GBP)dic 2023Variazione Y/Y
Investimenti cash/breve termine
44,06 Mln-49,34%
Totale attivo
133,82 Mln-5,03%
Totale passivo
46,57 Mln81,32%
Patrimonio netto totale
87,24 Mln
Azioni in circolazione
70,63 Mln
Prezzo/valore contabile
0,60
Redditività dell'attivo
-21,46%
Rendimento sul capitale
-28,44%
Flusso di cassa netto
(GBP)dic 2023Variazione Y/Y
Utile netto
-9,97 Mln-17,10%
Liquidità di esercizio
-9,65 Mln-59,94%
Contanti da investimenti
-7,47 Mln-3.853,70%
Contanti da finanziamenti
-1,72 Mln-1.360,85%
Flusso di cassa netto
-18,84 Mln-197,44%
Flusso di cassa libero
-3,81 Mln-56,02%
Informazioni
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Fondazione
2006
Sito web
Dipendenti
237
Ricerca
Cancella ricerca
Chiudi ricerca
App Google
Menu principale